Efficacy and safety of rademikibart (CBP-201), a next-generation monoclonal antibody targeting IL-4R α, in adults with moderate-to-severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001)

CONCLUSION: Rademikibart was efficacious and well tolerated at Q2W and Q4W intervals. Q4W dosing is a more convenient frequency than approved for current therapies.PMID:38157942 | DOI:10.1016/j.jaci.2023.11.924

Source: Herpes - December 29, 2023 Category: Infectious Diseases Authors: Jonathan I Silverberg Bruce Strober Brian Feinstein Jinhua Xu Emma Guttman-Yassky Eric L Simpson Pauline Li Malinda Longphre Jing Song Jiawang Guo Jang Yun Belinda Williams Wubin Pan Selwyn Ho Ra úl Collazo Zheng Wei Source Type: research